Adis, Auckland, New Zealand.
CNS Drugs. 2012 Sep 1;26(9):781-5. doi: 10.2165/11207570-000000000-00000.
Oral rasagiline (Azilect®) as monotherapy or as an adjunct to levodopa provides a useful option in the symptomatic treatment of adult patients with Parkinson's disease. In patients with early Parkinson's disease, monotherapy with rasagiline 1 mg/day improved symptoms of the disease relative to placebo. As adjunctive therapy to levodopa in patients with advanced Parkinson's disease, rasagiline 0.5 or 1 mg/day significantly reduces the total daily 'off' time. Rasagiline is generally well tolerated when administered as monotherapy or as adjunctive therapy.
口服雷沙吉兰（Azilect®）作为单药治疗或与左旋多巴合用，为成人帕金森病患者的症状治疗提供了一种有用的选择。在早期帕金森病患者中，雷沙吉兰 1mg/天的单药治疗相对于安慰剂改善了疾病症状。作为晚期帕金森病患者左旋多巴的辅助治疗，雷沙吉兰 0.5 或 1mg/天可显著减少每日总“关期”时间。雷沙吉兰作为单药或辅助治疗时通常具有良好的耐受性。
